drugset / Trial / NCT04873232
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Timeline
- Start
- 2021-05-17
- Primary completion
- 2023-09-14
- Completion
- 2024-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Engensis | Other / unclassified | — | Intramuscular |